Comparative Pharmacology
Head-to-head clinical analysis: DARVON N W ASA versus KESSO GESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON N W ASA versus KESSO GESIC.
DARVON-N W/ ASA vs KESSO-GESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception. Aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates pain, fever, and inflammation.
KESSO-GESIC is a combination analgesic containing butalbital (barbiturate), acetaminophen, and caffeine. Butalbital depresses the CNS by enhancing GABA-A receptor activity, acetaminophen inhibits COX enzymes centrally, and caffeine is a CNS stimulant that may enhance analgesia.
1-2 capsules (propoxyphene napsylate 100 mg / aspirin 325 mg per capsule) orally every 4 hours as needed for pain; maximum 6 capsules per day.
Adults: 2 tablets (325 mg acetaminophen + 5 mg hydrocodone per tablet) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
None Documented
None Documented
Propoxyphene: terminal elimination half-life is 6-12 hours in adults with normal renal function; norpropoxyphene has a longer half-life (30-36 hours). Aspirin (as salicylate): half-life is dose-dependent, ranging from 2-3 hours at low doses to 15-30 hours at anti-inflammatory doses (300-600 mg in Darvon-N W/ASA).
Terminal elimination half-life is 2–4 hours in healthy adults. In hepatic impairment, half-life may be prolonged up to 8 hours; in renal impairment, minimal change.
Renal: propoxyphene and its metabolites (norpropoxyphene) are primarily eliminated via kidneys, with ~20-25% excreted unchanged; fecal: minor; biliary: some enterohepatic recirculation occurs, but exact % are not well quantified for the combination product. Aspirin is hydrolyzed to salicylate, which is excreted renally (75% as salicyluric acid, 10% as salicylic acid, 10% as glucuronide conjugates, and minor amounts as gentisic acid).
Renal excretion of unchanged drug and metabolites: approximately 60% renal, 40% biliary/fecal. Major metabolites include glucuronide conjugates.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination